<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604288</url>
  </required_header>
  <id_info>
    <org_study_id>HBHOA01</org_study_id>
    <nct_id>NCT04604288</nct_id>
  </id_info>
  <brief_title>Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Hip Osteoarthritis</brief_title>
  <official_title>&quot;Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Hip Osteoarthritis&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <brief_summary>
    <textblock>
      This is an Individual Patient Expanded Access IND of autologous adipose derived Mesenchymal&#xD;
      Stem Cells with the primary goal of treating 1 individual with advanced left Hip&#xD;
      Osteoarthritis (HOA) who has exhausted all treatment options The subject will receive 1&#xD;
      autologous HB-adMSCs intravenous infusion of 200 million (2 x 10⌃8 cells) total cells, and 1&#xD;
      autologous HB-adMSCs intra-articular injection into the left hip of 100 million (1x10⌃8)&#xD;
      total cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once eligibility has been confirmed, the subject will return approximately 14 days later for&#xD;
      a single autologous HB-asMSC intra-articular injection in the left hip with 100 million&#xD;
      (1x10⌃8) cells/2ml. At this visit, the following procedures will occur:&#xD;
&#xD;
        -  A verification of patient consent will be verbally performed&#xD;
&#xD;
        -  Review of medical history, and concomitant medications.&#xD;
&#xD;
        -  Physical examination.&#xD;
&#xD;
        -  Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)&#xD;
&#xD;
        -  Weight measurement&#xD;
&#xD;
        -  Blood samples will be collected for baseline efficacy laboratory assessments:&#xD;
&#xD;
        -  Erythrocyte sedimentation rate and C-Reactive Protein.&#xD;
&#xD;
           •. A &quot;time-out&quot; verification of patient/consent/procedure/cell product will be performed&#xD;
           prior to intra-articular injection.&#xD;
&#xD;
        -  Baseline Pain assessments, Index of Severity and Disability scoring will be obtained at&#xD;
           this visit.&#xD;
&#xD;
        -  Adverse events monitoring The subject will then be monitored for a minimum of 1hr after&#xD;
           the investigational product administration.&#xD;
&#xD;
      Forty-eight hours (2 days) after the intra-articular injection, the subject will return for a&#xD;
      single autologous intravenous infusion of 2 x10⌃8 cells infused over 1 hour at 250mL/hr. The&#xD;
      patient will be closely monitored during the infusion and for a minimum of 1 hour after. At&#xD;
      this visit, the following procedures will occur:&#xD;
&#xD;
        -  A verification of patient consent will be verbally performed.&#xD;
&#xD;
        -  Review of medical history, and concomitant medications.&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)&#xD;
&#xD;
        -  Weight measurement&#xD;
&#xD;
        -  Patient pain assessment - Visual Analog Scale.&#xD;
&#xD;
        -  During this visit a video recording will be made with the purpose to capture patient's&#xD;
           overall status (gait, range of motion assessments, etc.).&#xD;
&#xD;
        -  Adverse events monitoring&#xD;
&#xD;
      Follow-up visits will occur at weeks 4 and 12. At these visits, the following procedures will&#xD;
      occur:&#xD;
&#xD;
        -  Review and update of medical history&#xD;
&#xD;
        -  Update concomitant medications list&#xD;
&#xD;
        -  Weight measurement&#xD;
&#xD;
        -  Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Blood samples will be collected:&#xD;
&#xD;
      Hematology Chemistry Coagulation Panel Erythrocyte sedimentation rate and C-Reactive Protein.&#xD;
&#xD;
        -  Patient pain assessment - Visual Analog Scale&#xD;
&#xD;
        -  Index of Severity for Osteoarthritis of the Hip by Lequesne et al.&#xD;
&#xD;
        -  WOMAC Survey Form&#xD;
&#xD;
        -  ICOAP: Measure of Intermittent and Constant OA Pain&#xD;
&#xD;
        -  During this visit a video recording will be made with the purpose to capture patient's&#xD;
           overall status (gait, range of motion assessments, etc.).&#xD;
&#xD;
        -  Adverse Events Monitoring&#xD;
&#xD;
      The End of Study Visit will occur at week 26. At this visit, the following procedures will&#xD;
      occur:&#xD;
&#xD;
        -  Review and update of medical history&#xD;
&#xD;
        -  Update concomitant medications list&#xD;
&#xD;
        -  Weight measurement&#xD;
&#xD;
        -  Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Blood samples will be collected:&#xD;
&#xD;
      Hematology Chemistry Coagulation Panel Erythrocyte sedimentation rate and C-Reactive Protein.&#xD;
&#xD;
        -  Patient pain assessment - Visual Analog Scale&#xD;
&#xD;
        -  Index of Severity for Osteoarthritis of the Hip by Lequesne et al.&#xD;
&#xD;
        -  WOMAC Survey Form&#xD;
&#xD;
        -  ICOAP: Measure of Intermittent and Constant OA Pain&#xD;
&#xD;
        -  During this visit a video recording will be made with the purpose to capture patient's&#xD;
           overall status (gait, range of motion assessments, etc.).&#xD;
&#xD;
        -  Adverse Events Monitoring&#xD;
&#xD;
        -  Chest X-ray (PA single view)&#xD;
&#xD;
        -  Hip MRI without contrast&#xD;
&#xD;
        -  During this visit a video recording will be made with the purpose to capture patient's&#xD;
           overall status (gait, range of motion assessments, etc.).&#xD;
&#xD;
        -  Adverse Events Monitoring&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Arthritis</condition>
  <condition>Hip Osteoarthritis</condition>
  <condition>Degenerative Arthritis</condition>
  <condition>Hip Arthritis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of Hip Osteoarthritis.&#xD;
&#xD;
          2. Hemodynamically stable.&#xD;
&#xD;
          3. Ability to obtain consent from the subject or Legal Authorized Representative (LAR).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunosuppression as defined by WBC &lt; 3, 000 cells/ml at baseline screening.&#xD;
&#xD;
          2. Other acute or chronic medical conditions that, in the opinion of the investigator,&#xD;
             may increase the risks associated with study participation or HB-adMSCs&#xD;
             administration.&#xD;
&#xD;
          3. Any abnormal, inexplicable laboratory result with no obvious cause defined.&#xD;
&#xD;
          4. Participation in other interventional research studies.&#xD;
&#xD;
          5. Unwillingness to return for follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>River Oaks Hospital and Clinics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cells</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Autologous Stem Cells</keyword>
  <keyword>Hope Biosciences</keyword>
  <keyword>Hope</keyword>
  <keyword>Hip</keyword>
  <keyword>MSC</keyword>
  <keyword>MSCs</keyword>
  <keyword>Intra-articular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

